GlassScriptPhysician profile
Jessica M Ruffin
NPI 1972514578
$3,499.48
in general payments reported to CMS, 2019-2025
36 companies · $805 in 2025
The $805 reported for 2025 was more than what 89% of Obstetrics providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $154 · 2021: $372 · 2022: $639 · 2023: $727 · 2024: $430 · 2025: $805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,862 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,861.88 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $587.59 | 2019-2025 | Lo Loestrin Fe, Orilissa, Liletta |
| Astellas Pharma US INC | $372.58 | 2019-2025 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $252.47 | 2019-2025 | Slynd |
| Biogen, INC. | $243.34 | 2024-2025 | Zurzuvae |
| Novo Nordisk INC | $200.18 | 2020-2025 | Wegovy |
| Channel Medsystems, INC. | $166.34 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $145.75 | 2019-2025 | |
| Coopersurgical, INC. | $144.54 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Daiichi Sankyo INC. | $140.94 | 2021-2024 | Injectafer |
| Hologic Sales and Service, LLC | $126.30 | 2022-2025 | Acessa Provu System, Fetal Fibronectin Enzyme Immunoassay, Omni Hysteroscope |
| Edwards Lifesciences Corporation | $109.09 | 2025 | Sapien 3 Ultra Resilia |
| Mayne Pharma Commercial LLC | $106.29 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $98.35 | 2019 | |
| Shield Therapeutics INC | $96.18 | 2023-2025 | Accrufer |
| Scynexis, INC. | $86.96 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $85.64 | 2021-2025 | |
| Boston Scientific Corporation | $74.40 | 2019-2025 | Axonics |
| Agile Therapeutics, INC. | $58.35 | 2021-2022 | |
| Organon LLC | $55.63 | 2024 | |
| Merck Sharp & Dohme LLC | $32.81 | 2022-2023 | Gardasil 9 |
| Monaghan Medical Corporation | $29.71 | 2024 | Aerobika |
| Medtronic, INC. | $28.27 | 2023 | Truclear |
| Therapeuticsmd, INC. | $25.50 | 2021 | |
| Amag Pharmaceuticals, INC. | $25.44 | 2019 | |
| Optumhealth Care Solutions, LLC | $24.37 | 2024 | Vivify Health Care Team Portal 001, Eitan Medical |
| Mylan Pharmaceuticals INC. | $24.37 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $22.10 | 2025 | Myfembree |
| Aspira Women'S Health INC | $21.90 | 2021 | |
| Northgate Technologies, INC. | $21.72 | 2024 | Stimsite |
| Pacira Pharmaceuticals Incorporated | $21.68 | 2024 | Exparel |
| Virtus Pharmaceuticals LLC | $12.69 | 2021 | |
| Amgen INC. | $12.26 | 2019 | |
| Evofem Biosciences, INC. | $11.60 | 2021 | |
| Allergan, INC. | $11.50 | 2019 | |
| Lupin INC. | $11.33 | 2020 | |
| Vertical Pharmaceuticals, LLC | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Ruffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.